Numerous novel and effective therapeutic agents and clinical trials addressing castration-resistant prostate cancer (CRPC) were reported during the 2023 American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. Notably, radionuclide drug conjugates (RDC), specifically 177Lu/111In-J591 and 225Ac-J591, exhibited enhanced therapeutic efficacy in treating patients with CRPC. Furthermore, promising treatment approaches for CRPC included dual anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death-1 (PD-1) blockade in rare tumors (DART)-Lorigerlimab, prostate stem cell antigen (PSCA)-directed chimeric antigen receptor (CAR)-T cell immunotherapy-BPX-601, and protein kinase inhibitor (AKTi)-CAPltello-280. We have summarized the latest CRPC treatment strategies presented at the 2023 ASCO-GU Cancers Symposium, along with recent advances in CRPC clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391859 | PMC |
| http://dx.doi.org/10.1186/s40164-023-00430-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characterization changes and research waste in randomized controlled trials of global gastroesophageal reflux disease and hiatus hernia over the past 20 years.
Int J Surg
January 2025
Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Background: The results of many large randomized clinical trials (RCTs) have transformed clinical practice in gastroesophageal reflux disease (GERD) and esophageal hiatal hernia (HH). However, research waste (i.e.
View Article and Find Full Text PDFGlobal trends in surgically based treatment of anal fistula in Crohn's disease: a bibliometric and visualization analysis.
Int J Surg
January 2025
Department of Anorectal Surgery, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Background: Crohn's disease (CD) is a chronic, recurrent gastrointestinal disorder characterized by a complex etiology. Among its perianal complications, anal fistulas represent a challenging comorbidity. With the increase of surgical options, a comprehensive bibliometric analysis was deemed necessary to consolidate the vast array of research in this field.
View Article and Find Full Text PDFCharacteristics of Trials Preceding FDA Approval of Novel Psychiatric Drugs.
JAMA Netw Open
January 2025
Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts.
Contemporary Insights into LMNA Cardiomyopathy.
Curr Cardiol Rep
January 2025
Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Purpose Of Review: This review aims to explore how a diagnosis of LMNA-related cardiomyopathy (LMNA-CM) informs clinical management, focusing on the prevention and management of its complications, through practical clinical strategies.
Recent Findings: Longitudinal studies have enhanced our understanding of the natural history of LMNA-CM including its arrhythmic and non-arrhythmic complications. A LMNA specific ventricular arrhythmia risk prediction strategy has been integrated into clinical practice guidelines.
New generation low level laser effect on masseter muscle oxygenation, bite force and algometric changes in myofacial pain syndrome: a randomised, placebo-controlled clinical trial.
Lasers Med Sci
January 2025
University of Zurich, Zurich, Switzerland.
The aim of this study was to compare the effectiveness of different types of low level laser treatment (LLLT) in reducing pain levels, changing oxygen saturation and bite force in patients with myofacial pain syndrome (MPS). 45 patients were randomly assigned to three groups: Group 1 (GRR laser, n = 15) received LLLT with Gallium-Aluminium-Arsenide (GaAlAs) diode laser with a wavelength of 904 nm and red laser with a wavelength of 650 nm over masseter muscle region. Group 2 (Nd: YAG laser, n = 15) were treated with Neodymium-doped Yttrium Aluminium Garnet laser with a wavelength of 1064 nm and the same protocol with Nd: YAG laser was performed in the Group 3 (placebo, n = 15) using sham device.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!